Asia On The Move: China Healthcare Reform Head Leaves
This article was originally published in PharmAsia News
Executive Summary
Sun Zhigang is leaving his cabinet position in China to become the deputy head of southwestern Guizhou province, leaving many wondering about the future direction of the massive effort to provide universal health coverage, improve quality and reduce costs for China’s population. Personnel changes are also taking place at Sanofi and Eisai in Japan, GSK in Southeast Asia and the Chinese association Sino-PhiRDA.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.